Alerts, recalls and safety information
This safety information is provided by the Medicines and Healthcare products Regulatory Agency (MHRA), the UK regulator for medicines and medical devices. These alerts may cover medicines, vaccines or medical devices, and can include new safety warnings, prescribing advice, product recalls or field safety notices. They are issued to protect patients and to help healthcare professionals provide safe, effective care.
Patient.info republishes these updates so that both professionals and the public can access the latest official safety communications in one place.

Featured articles
A%2F42/og.png)
Class 2 Medicines Recall: Norgine Pharmaceuticals Limited, Pedmarqsi 80 mg/mL solution for infusion, EL(26)A/42
by Medicines and Healthcare products Regulatory Agency (MHRA)

Nova Biomedical StatStrip ketone test strips: risk of disruption to blood ketone testing due to quality-control failures and supply interruption DSI/2026/013
by Medicines and Healthcare products Regulatory Agency (MHRA)

Field Safety Notices for October 2026
by Medicines and Healthcare products Regulatory Agency (MHRA)

Field Safety Notices: 28 September 2026 to 2 October 2026
by Medicines and Healthcare products Regulatory Agency (MHRA)
Field Safety Notices: 19 to 23 October 2026List of Field Safety Notices from 19 to 23 October 2026. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in use across the NHS and...
MHRA Safety Roundup: October 2026Summary of the latest safety advice for medicines and medical device users Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in use...
#MedSafetyWeek (2 to 8 November 2026): Don't ignore suspected side effects, report them! Updates to the Yellow Card website and appThe annual #MedSafetyWeek campaign is taking place from 2 to 8 November 2026 to promote the importance of reporting side effects from medicines and medical device incidents. This year's theme is ‘Side effects: don't … Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regula...
Class 2 Medicines Recall: Xeal Pharma, Clopidogrel Oral Liquids (all strengths), EL(26)A/43Xeal Pharma have informed MHRA that all strengths of their Clopidogrel Oral Suspension and Clopidogrel Oral Solution products contain less than the labelled amount of clopidogrel. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medica...
IXCHIQ Chikungunya vaccine: UK marketing authorisation withdrawn following safety reviewFollowing advice from the Commission on Human Medicines (CHM), the MHRA has concluded that the benefit-risk balance for the IXCHIQ chikungunya vaccine is no longer considered favourable and the UK marketing authorisation has… Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’...
Field Safety Notices: 5 to 9 October 2026List of Field Safety Notices from 5 to 9 October 2026. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in use across the NHS and w...
Field Safety Notices: 12 October 2026 to 16 October 2026List of Field Safety Notices: 12 October 2026 to 16 October 2026 Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in use across the...
Field Safety Notices: 27 to 31 January 2025List of Field Safety Notices from 27 to 31 January 2025. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in use across the NHS and...
Antidepressants: new safety measures for all patients to improve communication of the risk of suicidal thoughts and behaviours and persistent sexual dysfunctionNew safety measures are now being implemented to improve how the risks of suicidal thoughts and behaviours and persistent sexual dysfunction are communicated to patients taking antidepressant medications. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medic...
Continuous renal replacement therapy (CRRT): Consider delayed administration of concurrent echinocandins, such as caspofungin, to reduce the risk of adsorption onto new polyacrylonitrile (PAN)-based filter membranes DSI/2026/014Continuous renal replacement therapy (CRRT) is used for managing severe acute kidney injury and fluid overload. Published evidence has shown that caspofungin can bind to polyacrylonitrile (PAN)-based membranes used in CRRT w… Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’...
Class 2 Medicines Recall: Norgine Pharmaceuticals Limited, Pedmarqsi 80 mg/mL solution for infusion, EL(26)A/42Norgine Pharmaceuticals Limited is recalling the batches listed in the table due to risk of particulate matter being present in the product identified during routine stability investigations. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccine...
Nova Biomedical StatStrip ketone test strips: risk of disruption to blood ketone testing due to quality-control failures and supply interruption DSI/2026/013Nova Biomedical has identified quality issues affecting specified lots of StatStrip ketone test strips. The affected lots have been associated with quality-control (QC) failures and Nova Biomedical has initiated a recall, ad… Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’...
Field Safety Notices for October 2026Field Safety Notices for October 2026 Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in use across the NHS and wider healthcare s...
Field Safety Notices: 28 September 2026 to 2 October 2026List of Field Safety Notices: 21 to 25 September 2026 Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in use across the NHS and wi...
Class 3 Medicines Recall: Norgine Limited, MOVICOL Plain 13.7g powder for oral solution, EL(26)A/41Norgine Limited is recalling specific batches of product as a precautionary measure due to some units containing the incorrect amounts of active ingredients. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its...
Class 4 Medicines Defect Notification: Neuraxpharm UK Limited, Levetiracetam Neuraxpharm granules for oral solution in sachet, EL(26)A/40Neuraxpharm UK Limited have informed the MHRA that a review of the approved Patient Information Leaflet (PIL) has identified discrepancies between the current Neuraxpharm product safety information and the corresponding refe… Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’...
Field Safety Notices: 21 to 25 September 2026List of Field Safety Notices from 21 to 25 September 2026. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in use across the NHS a...
MHRA Safety Roundup: September 2026Summary of the latest safety advice for medicines and medical device users Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in use...
Class 4 Medicines Defect Notification: B. Braun Melsungen AG, Meropenem 1000 mg powder and solvent for solution for infusion, EL(26)A/39B. Braun Melsungen AG has notified the MHRA that errors have been identified in the Patient Information Leaflet (PIL) included in some batches of Meropenem 1000 mg powder and solvent for solution for infusion. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for...
Field Safety Notices: 14 to 18 September 2026List of Field Safety Notices from 14 to 18 September 2026. Read the full update from MHRA About MHRA alerts and recalls The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulator for medicines, vaccines and medical devices. One of its key responsibilities is to monitor the safety and effectiveness of products in use across the NHS a...